Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 8, 2013, Pages 4765-4768

  Song, Xiao Yun ^a   Zhou, Shi Jie ^a   Xiao, Ning ^a   Li, Yun Song ^a   Zhen, De Zhi ^a   Su, Chong Yu ^a   Liu, Zhi Dong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

IL 6; IL 8; Non small cell lung cancer; Serum values; TNF ; VEGF

Indexed keywords

AUTACOID; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885778852     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.8.4765     Document Type: Article

References (23)

1. Beasley MB, Brambilla E, Travis WD (2005). The 2004 World Health Organization classification of lung tumors. Semin Roentgenol, 40, 90-7.
2. Bodelon C, Polley MY, Kemp TJ, et al (2013). Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol, 24, 2073-9.
3. Boldrini L, Calcinai A, Samaritani E, et al (2000). Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer, 83, 480-6.
4. Cheng D, Kong H, Li Y (2013). Prognostic values of VEGF and IL-8 in malignant pleural effusion in patients with lung cancer. Biomarkers, 18, 386-90.
5. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7.
6. Dalaveris E, Kerenidi T, Katsabeki-Katsafli A, et al (2009). VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer, 64, 219-25.
7. Ferlay J, Autier P, Boniol M, et al (2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol, 18, 581-92.
8. Grivennikov SI, Greten FR, Karin M (2010). Immunity, inflammation, and cancer. Cell, 140, 883-99.
9. Hashimoto K, Ikeda Y, Korenaga D, et al (2005). The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer, 103, 1856-64.
10. Il'yasova D, Colbert LH, Harris TB, et al (2005). Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev, 14, 2413-8.
11. Lagiou P, Trichopoulos D (2011). Inflammatory biomarkers and risk of lung cancer. J Natl Cancer Inst, 103, 1073-5.
12. Matsuyama W, Hashiguchi T, Mizoguchi A, et al (2000). Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest, 118, 948-51.
13. Millar HJ, Nemeth JA, McCabe FL, et al (2008). Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model. Cancer Epidemiol Biomarkers Prev, 17, 2180-7.
14. Peto R, Darby S, Deo H, et al (2000). Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ, 321, 323-9.
15. Pine SR, Mechanic LE, Enewold L, et al (2011). Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst, 103, 1112-22.
16. Saito A, Suzuki HI, Horie M, et al (2013). An integrated expression profiling reveals target genes of TGF-beta and TNF-alpha possibly mediated by microRNAs in lung cancer cells. PLoS One, 8, e56587.
17. Scott HR, McMillan DC, Forrest LM, et al (2002). The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer, 87, 264-7.
18. Siemes C, Visser LE, Coebergh JW, et al (2006). C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol, 24, 5216-22.
19. Takigawa N, Segawa Y, Fujimoto N, et al (1998). Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res, 18, 1251-4.
20. Tas F, Duranyildiz D, Argon A, et al (2005). Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol, 22, 353-8.
21. Tas F, Duranyildiz D, Oguz H, et al (2006). Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest, 24, 576-80.
22. Volm M, Koomagi R, Mattern J (1999). PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res, 19, 651-5.
23. Wojcik E, Jakubowicz J, Skotnicki P, et al (2010). IL-6 and VEGF in small cell lung cancer patients. Anticancer Res, 30, 1773-8.